Table 2_Dynamic hyperinflammatory response assessment using HIC scores in COVID-19: applic

A retrospective analysis of 218 hospitalized COVID-19 patients with hyperinflammation (HIC ≥35) who received anakinra at a tertiary referral center. The dataset likely contains daily clinical and laboratory parameters used to assess treatment response and mortality outcomes. The data was uploaded to figshare by Shirkhan Amikishiyev in May 2026.

Use Cases

• Predicting in-hospital mortality based on HIC score dynamics and CRP reduction time.
• Analyzing the relationship between ΔHIC and other inflammatory biomarkers like neutrophil count, D-dimer, LDH, procalcitonin, and creatine kinase.
• Evaluating the diagnostic and monitoring utility of the HIC score during IL-1 blockade therapy.
• Identifying optimal timing and thresholds for initiating and reassessing anakinra treatment.

Strengths

• Includes 218 patient records from a specific clinical cohort.
• Provides specific mortality rate (12.8%) and comparative metrics like CRP reduction time (3.1 vs. 4.7 days).
• Contains ROC analysis results with AUC values (0.75) and cut-off scores (70.8, 66.5) for HIC.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect bias inherent to a single tertiary referral center.

Provenance

Source

figshare

Collection Method

Retrospective analysis of hospitalized patients.

Freshness

Last updated 2026-05-22 05:33:55; freshness should be verified.